Top Health-care stocks:
Health-care shares were mixed in pre-market trade Friday.
In health-care stocks news, Myriad Genetics ( MYGN ) said Friday that a study shows that its BRACAnalysis CDx test successfully identified patients with HER2-negative metastatic breast cancer who have BRCA mutations and who had improved response with Lynparza, AstraZeneca's ( AZN ) PARP inhibitor.
Shares in the company were 0.1% lower at $17.25 pre-bell. The stock has traded between $15.15 and $39.74 over the past 52 weeks.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.